1.. Introduction {#S5}
================

Prostate cancer is bone-tropic, rendering it particularly susceptible to treatments that target bone formation and osteoblastic activity. The cancer-induced abnormal bone metabolism that places patients at risk of death and morbidity can also be leveraged to deliver life-prolonging therapy.

Radium 223 dichloride (radium-223), a calcium mimetic alpha particle--emitting radiopharmaceutical, targets hydroxyapatite. It selectively accumulates in areas of increased bone turnover that surround metastatic lesions, where it emits four high-energy, short-range (\<100 μm) alpha particles with resulting minimal radiation effects on the adjacent bone marrow \[[@R1],[@R2]\]. In preclinical models, it reduces abnormal bone production, tumour burden and dysregulated bone deposition \[[@R3],[@R4]\]. Clinically, radium-223---given at a dose of 55 kBq/kg every 4 weeks for 6 doses---prolongs life and the time to first symptomatic skeletal event in patients with bone-predominant metastatic castration-resistant prostate cancer (mCRPC) and no known visceral metastases \[[@R5]\].

Docetaxel is a chemotherapeutic agent that interferes with microtubule dynamics and has a radiosensitising effect \[[@R6]\]. Docetaxel given at a dose of 75 mg/m^2^ every 3 weeks (q3w) in combination with prednisone prolongs life in patients with mCRPC \[[@R7]\].

We hypothesised that combining bone-targeted alpha radiation therapy with chemotherapy in patients with mCRPC might be an effective treatment approach, predicated on the concepts of multicompartment targeting and possible cross-sensitisation in bone lesions \[[@R8]\]. We conducted a phase 1/2a study to investigate this combination.

2.. Patients and methods {#S6}
========================

2.1.. Patients {#S7}
--------------

Eligible patients had progressive mCRPC with ≥2 bone metastases, testosterone ≤50 ng/dL, Karnofsky Performance Status of ≥70%, life expectancy of ≥6 months and adequate organ functionality (white blood cell count ≥3 × 10^9^/L, with an absolute neutrophil count ≥1.5 × 10^9^/L, a platelet count ≥100 × 10^9^/L and haemoglobin ≥10.0 g/dL; total bilirubin level ≤ upper limit of normal (ULN) and aspartate aminotransferase and alanine aminotransferase concentrations ≤1.5 × ULN; creatinine ≤1.5 × ULN and albumin \>30 g/L). The patients-needed to have had two consecutive prostate-specific antigen (PSA) increases at least one week apart, with a minimum value of 2 ng/mL at screening, or two or more new bone lesions when analysed by bone scintigraphy. Those patients on a first-generation androgen inhibitor needed to progress through a 4-week withdrawal. The exclusion criteria included the following: visceral metastases, defined as \>2 lung metastases and/or liver metastases that were ≥2 cm in size, symptomatic nodal disease and malignant lymphadenopathy \>3 cm in short-axis diameter. Patients should not have received \>10 previous docetaxel doses or previous treatment with a bone-seeking radiopharmaceutical.

2.2.. Study design {#S8}
------------------

This two-part phase 1/phase 2a study, conducted at eight centres, seven in the United States and one in France, aimed to establish a recommended phase 2 dose (RP2D) of radium-223 in combination with docetaxel and to investigate safety and exploratory efficacy end-points at the RP2D.

In phase 1, between 9 and 18 patients were to be enrolled and treated according to a 3 + 3 design. The dose escalation scheme is shown in [Fig. 1A](#F1){ref-type="fig"}. Dose-limiting toxicity (DLT) was assessed during the 6-week period after the first radium-223 injection. DLT was defined as absolute neutrophil count \<0.5 × 109/L for \>7 days without fever despite granulocyte-colony stimulating factor support, grade ≥3 febrile neutropenia (after a protocol amendment), platelet count \<25 × 10^9^/L for \>7 days, grade ≥3 diarrhoea despite optimal medical management, grade ≥4 vomiting or constipation.

Radium-223 was started at a dose of 27.5 kBq/kg (according to the National Institute of Standards and Technology \[NIST\] 2016 update \[[@R9]\]), every six weeks (q6w), and could be escalated to 55 kBq/kg (according to NIST 2016 update \[[@R9]\]). The starting dose of docetaxel was 75 mg/m^2^ q3w, with a planned reduction to 60 mg/m^2^ in the event of DLT. We prioritised achieving full-dose radium-223 over full-dose chemotherapy in the dose escalation scheme, given that there are survival data using docetaxel as part of combination therapy at its step-down dose but no survival data using a lower dose of radium-223 \[[@R10]\]. Radium-223 was administered every other chemotherapy dose rather than monthly to optimise the likelihood of patient acceptance and compliance by having only one day of treatment per cycle, at a dosing interval known to have favourable clinical effects \[[@R11]\]. The number of doses was capped at five in an abundance of caution to protect long-term marrow integrity in the event of enhanced toxicity that would not be detected by blood count assessments during treatment. In all cohorts, docetaxel was to be administered every 3 weeks and was to be continued in the absence of progressive disease or unacceptable toxicity. Docetaxel and radium-223 were administered on the same day, with docetaxel administered first, followed by radium-223 as soon as practically feasible. Prednisone 5 mg was given orally twice daily, continuously. Dexamethasone premedication was given before docetaxel dosing as per each institution's practice. Growth factor support was allowed only as secondary prophylaxis.

In phase 2a, using a schedule generated by an independent statistician, patients were randomly assigned centrally 2:1, using a block randomisation scheme (block size of three), via an interactive voice response system, to combination therapy or docetaxel alone, respectively. A preplanned early stopping rule applied in the event of significant toxicity in the combination arm. The treatment period was a maximum of 30 weeks (10 doses of docetaxel), followed by 22 weeks of follow-up.

The study was conducted in accordance with the Declaration of Helsinki and the International Conference on Harmonisation E6, Good Clinical Practice. The protocol and all amendments were approved by the independent ethics committee/institutional review boards at each site, and written informed consent was obtained from the patients before any assessments were performed.

2.3.. Assessments {#S9}
-----------------

Adverse events (AEs) were coded according to the Medical Dictionary for Regulatory Activities version 13.0. Severity was graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events version 4.0. The safety assessment period for AEs was from the start of study treatment to 6 weeks after the end of study treatment (8 weeks for serious AEs \[SAEs\]). Data on marrow sequelae and any second malignancies were collected up to 12 months after the start of study treatment. Exploratory efficacy assessments included on-treatment changes in bone alkaline phosphatase (bALP), total ALP (tALP), uri-nary C-telopeptide of type 1 (uCTX-1), N-terminal propeptide of procollagen type 1 (P1NP), pyridinoline cross-linked carboxyterminal telopeptide (ICTP), PSA and circulating tumour cells (CTCs).

2.4.. Statistical considerations {#S10}
--------------------------------

The primary objectives were to establish a recommended dose of radium-223 combined with docetaxel and to investigate safety and explore efficacy at this dose level. The safety population included all patients who received treatment. To examine the antitumour effect of treatment in this exploratory study, the efficacy population comprised patients who received ≥40% (2 infusions) of the specified number of radium-223 doses (combination arm) or docetaxel doses (docetaxel arm) and had no major protocol violations (per protocol population). No formal statistical testing was planned.

Exploratory efficacy end-points included time to PSA progression, time to bALP progression, time to tALP progression, time to first radiographic or clinical progression based on Response Evaluation Criteria in Solid Tumours (RECIST) \[[@R12]\] version 1.1 and Prostate Cancer Working Group 2 (PCWG2) \[[@R13]\] definitions and overall survival. Time-to-event end-points were measured from the first dose of study treatment. For this report, progression-free survival (PFS) events are defined as radiographic or clinical progression or death. Medians for time-to-event variables were estimated using the Kaplan--Meier method. Changes in biomarkers over time were computed as the area under the bone marker curve. Based on the Lehmann alternative power function for a two-sided 0.05-level test, the planned 42 patients were to be randomised. Assuming for a given marker that the odds were 3:1 that a patient in the combination group had a greater area under the bone turnover curve relative to a patient in the docetaxel group, the power of the test was 0.78. *P* values for exploratory efficacy end-points have not been corrected for multiplicity of testing and are provided for information only.

3.. Results {#S11}
===========

3.1.. Phase 1 dose escalation {#S12}
-----------------------------

Seventeen patients were treated in the phase 1 dose escalation cohort, including three with visceral disease; patient disposition and baseline characteristics are summarised in [Fig. 1B](#F1){ref-type="fig"} and [Supplementry Table 1](#SD1){ref-type="supplementary-material"}. No DLTs occurred among the first three patients treated at full-dose chemotherapy and half-dose radium-223 (27.5 kBq/kg), but two developed febrile neutropenia, which was not then specified as a DLT. The cohort was expanded to six patients; no DLTs or additional febrile neutropenia events were seen. Owing to febrile neutropenia in two of six patients, the docetaxel dose was reduced to 60 mg/m^2^ in the second cohort, which also used radium-223 at a dose of 27.5 kBq/kg. No DLTs were seen in the first three patients enrolled in this cohort. Because it appeared that the docetaxel dose at 75 mg/m^2^ was accounting for the neutropenic fevers, the radium-223 dose was escalated to 55 kBq/kg in the third cohort, holding the docetaxel dose at 60 mg/m^2^. No DLTs were seen in the first three patients enrolled at this dose level. However, one patient developed grade 3 neutropenia and another developed grade 4 neutropenia, both without fever or infection. After reviewing the safety data, it was decided to add three more patients to this cohort. No DLTs occurred in these patients. The third cohort dose (55 kBq/kg radium q6w × 5 and 60 mg/m^2^ docetaxel q3w × 10) was consequently selected as the RP2D to be administered over 30 weeks. Haematological treatment-emergent AEs (TEAEs) occurring in phase 1 are shown in [Supplementary Table 2](#SD1){ref-type="supplementary-material"}.

3.2.. Phase 2a cohort {#S13}
---------------------

### 3.2.1.. Patients and treatment {#S14}

Between December 19, 2012, and April 7, 2014, 53 patients were randomly assigned to receive combination therapy with docetaxel 60 mg/m^2^ and radium-223 55 kBq/kg q6w × 5 (n = 36) or docetaxel alone, at a standard dose of 75 mg/m^2^ q3w × 10 (n = 17, [Fig. 1C](#F1){ref-type="fig"}, [Supplementary Fig. 1](#SD1){ref-type="supplementary-material"}); seven patients were found not to be eligible and were not treated. Baseline characteristics were similar between treatment groups ([Table 1](#T1){ref-type="table"}). Seven (15%) of 46 eligible patients had visceral metastases at baseline, five in the combination arm and two in the docetaxel arm.

### 3.2.2.. Treatment exposure {#S15}

The patients in the combination arm received a cumulative median of 1187 mg of docetaxel (range, 250--1520), versus 1270 mg (range, 643--1600) in the docetaxel monotherapy arm. The median number of docetaxel doses was 10 (range, 2--11) in the combination arm and 9 (range, 4--10) in the monotherapy arm. The median number of radium-223 doses in the combination arm was 5 (range, 1--5).

In the combination therapy arm, radium-223 and docetaxel administration was delayed in two patients because of TEAEs (cellulitis and osteoporosis), with docetaxel administration delayed in a further five patients (because of back pain, pain in extremity; oral abscess; pneumonia; toothache; diarrhoea, dehydration, pleural effusion, acute respiratory failure and pneumonia). There were three dose delays because of TEAEs in the docetaxel arm (hypotension; influenza-like illness, cough and melaena; cellulitis). In the combination arm, radium-223 and docetaxel were discontinued in 4 of 33 (12%) patients because of TEAEs (unilateral blindness; cerebrovascular accident; pneumonitis; asthenia and back pain), and docetaxel was discontinued in a further two (6%) patients (peripheral neuropathy; asthenia). In the docetaxel arm, 3 of 13 (23%) patients discontinued treatment because of TEAEs (febrile neutropenia; interstitial lung disease; peripheral neuropathy).

### 3.2.3.. Safety {#S16}

TEAE and TESAE incidence in the phase 2a safety population is summarised in [Table 2](#T2){ref-type="table"} and [Supplementary Table 3](#SD1){ref-type="supplementary-material"}. Notably, there was less toxicity of any grade seen with combination therapy than docetaxel alone for neutropenia, febrile neutropenia, fatigue, dyspnoea, arthralgia and nausea. However, combination therapy was associated with more diarrhoea and back pain. The incidence of grade 3 or 4 TEAEs was low in both arms ([Table 2](#T2){ref-type="table"}), with the exception of neutropenia. Febrile neutropenia occurred in two patients (one grade 3 and one grade 4) in the docetaxel arm and none in the combination arm; growth factors were used to prevent or resolve neutropenia in four patients in the combination arm and two patients in the docetaxel arm. There were no TEAEs of thrombocytopenia reported in either arm during the treatment period, and median platelet laboratory values were similar for both treatment groups between baseline and day 8 ([Supplementary Fig. 2](#SD1){ref-type="supplementary-material"}). There were no grade 5 TEAEs. No fractures were observed.

### 3.2.4.. Efficacy {#S17}

PSA declines of \>50% occurred in 61% of patients in the combination arm and 54% of patients in the docetaxel arm ([Supplementary Fig. 3A](#SD1){ref-type="supplementary-material"}). Plots of PSA level relative to baseline from week 4 to end of treatment show similar profiles for both arms, but PSA suppression was more pronounced with the combination arm ([Supplementary Fig. 4A](#SD1){ref-type="supplementary-material"}, [Supplementary Table 4](#SD1){ref-type="supplementary-material"}). A longer time to PSA progression was also observed with the combination arm ([Fig. 2A](#F2){ref-type="fig"}; median, 6.6 vs 4.8 months).

The median PFS was 12.0 months in the combination arm and 9.3 months in the docetaxel arm ([Fig. 2D](#F2){ref-type="fig"}). Twelve-month overall survival rates were similar (89% and 90%, respectively), although the high level of censoring precluded meaningful analysis. Disease progression based on RECIST and PCWG2 criteria is shown in [Supplementary Table 5](#SD1){ref-type="supplementary-material"}.

Changes in bone marker levels indicated a greater suppression of osteoblastic activity in the combination arm ([Supplementary Fig. 3B](#SD1){ref-type="supplementary-material"}, [3C](#SD1){ref-type="supplementary-material"}, [4B](#SD1){ref-type="supplementary-material"}, [C](#SD1){ref-type="supplementary-material"}, [Supplementary Table 4](#SD1){ref-type="supplementary-material"}). For both tALP and bALP, a longer median time to progression was observed for combination arm patients than docetaxel arm patients (9.0 vs 6.9 and 9.3 vs 7.4 months, respectively; [Fig. 2B](#F2){ref-type="fig"} and [C](#F2){ref-type="fig"}).

P1NP showed a decline pattern favouring the combination similar to that for bALP ([Supplementary Fig. 3D](#SD1){ref-type="supplementary-material"}, [4D](#SD1){ref-type="supplementary-material"}). The weighted median area under the timeeactivity curve for P1NP was substantially smaller for the combination arm (25.0 *v* 46.2 μg\*day/L), reflecting greater suppression of this marker ([Supplementary Table 6](#SD1){ref-type="supplementary-material"}).

Markers of osteoclastic activity, uCTX-1 and ICTP, showed similar patterns of decrease during treatment for combination arm and docetaxel arm patients ([Supplementary Fig. 3E](#SD1){ref-type="supplementary-material"}, [3F](#SD1){ref-type="supplementary-material"}, [Fig. 4E](#SD1){ref-type="supplementary-material"}, [F](#SD1){ref-type="supplementary-material"}, [Supplementary Table 6](#SD1){ref-type="supplementary-material"}).

An antitumour treatment effect in both arms was suggested by the decrease in CTCs ([Supplementary Table 7](#SD1){ref-type="supplementary-material"}).

4.. Discussion {#S18}
==============

To our knowledge, this trial is the first to explore the concept of dual targeting of osteoblastic bone and cancer cells using two concurrent agents, radium-223 and docetaxel, both of which prolong survival in patients with mCRPC. The concept of targeting bone and tumour is not novel. Prior studies have examined docetaxel in combination with bone-targeting agents that are not known to prolong survival, namely, strontium-89 and rhenium-188-hydroxyethylidine diphosphonate \[[@R14],[@R15]\]. These studies only used one or two doses of the bone-seeking radiopharmaceutical, rather than as a repetitively dosed regimen integrated with chemotherapy. Neither of these studies yielded data sufficiently promising to warrant advancement to phase 3. This study, however, used only life-prolonging agents in a regimen in which patients were exposed to both agents throughout the treatment. Although the combination arm used the step-down dose of docetaxel commonly applied in clinical practice, the cumulative exposure to docetaxel in the two arms of the phase 2a cohort was similar, and the combination was associated with less neutropenia, fatigue, and certain gastrointestinal toxicities. Another factor that may have contributed to the safety profile of the combination is that we administered five doses of radium q6w, rather than six doses every four weeks. Combination therapy appeared to increase the proportion of patients with substantial declines in levels of PSA and bone formation biomarkers relative to docetaxel alone and appeared to delay time to progression of these markers.

The safety of this combination is increasingly clinically relevant. Patients generally receive abiraterone or enzalutamide as first-line therapy for mCRPC, with chemotherapy reserved for second-line or beyond. After abiraterone or after enzalutamide therapy, patients frequently manifest both bony disease and soft tissue disease \[[@R16],[@R17]\] and remain sensitive to chemotherapy despite the presence of molecular changes that may render tumours resistant to further androgen receptor (AR)--directed therapy \[[@R18]\]. We therefore have an increasing clinical need for a regimen that is non-AR directed and delivers potent therapy both systemically to the cancer cells and also to the osteoblasts surrounding metastatic bone lesions. Radium-223 and docetaxel appear to fulfil these criteria well. This trial suggests that such an approach is safe, with patients followed up for 1 year without the emergence of long-term safety concerns. It is unknown whether the combination prolongs overall survival compared with radium-223 or docetaxel alone, thus warranting further investigation.

5.. Conclusions {#S19}
===============

This study showed that radium-223 (55 kBq/kg q6w) plus docetaxel (60 mg/m^2^ q3w) was well tolerated and presented no greater safety concerns than docetaxel alone (75 mg/m^2^ q3w). Exploratory efficacy data suggested enhanced antitumour activity in the combination arm. Based on these results, the radium-223/docetaxel combination will be further explored in a phase 3 trial in patients with bone metastatic CRPC ([NCT03574571](https://clinicaltrials.gov/ct2/show/NCT03574571)).
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![Study profile. (A) Dose escalation scheme.\*A return to the very first dose cohort could be considered in the event of 0/3 or \<2/6 DLTs at 55 kBq/kg radium-223 + 60 mg/m^2^ docetaxel q3w. If then 2/3 or ≥2/6 DLTs occurred at docetaxel 75 mg/m^2^, the chosen regimen for the phase 2a cohort was to be radium-223 50 kBq/kg × 5 + docetaxel 60 mg/m^2^ q3w × 10. (B) Phase 1 dose escalation cohorts. \*One patient was replaced, unable to receive both combined doses of radium-223 and docetaxel because of docetaxel hypersensitivity. ^†^Withdrew before receiving both doses of radium-223 to receive another treatment deemed necessary by the study sponsor. ^‡^Withdrew after receiving both doses of radium-223, too ill to attend the 12-month follow-up visit. (C) Phase 2a safety and efficacy cohort.\*25 patients in the combination arm received all planned radium-223 doses, 20 patients in the combination arm and 5 patients in the docetaxel arm received all planned docetaxel doses; the dose for 4 patients in the docetaxel arm was stepped down to 60 mg/m^2^. The study was completed through 12 months of follow-up from the start of treatment with 23 (70%) patients in the combination arm and 9 (69%) in the docetaxel arm. ^†^Received at least 40% of drug dose, no protocol violation. ^¥^Including the one patient who was excluded from the per protocol population. ^†^All deaths occurred during follow-up and were due to disease progression. ^§^3 patients entered hospice, and 1 had disease progression. PD, progressive disease; DLT, dose-limiting toxicity; ITT, intention to treat; q3w, every 3 weeks; q6w, every 6 weeks.](nihms-1621413-f0001){#F1}

![KaplaneMeier plots for (A) time to PSA progression; (B) time to tALP progression; (C) time to bALP progression and (D) radiographic or clinical progression-free survival. \*Per protocol population; intent-to-treat patients who received ≥40% of specified number of radium-223 injections or docetaxel, per dose escalation study results, and have no major protocol violations. ^†^As per Prostate Cancer Working Group 2 (PCWG2). PSA progression for patients with an initial PSA decline from baseline is defined as a PSA increase ≥25% and ≥2 ng/mL above nadir, confirmed ≥3 weeks later; for those with no PSA decline from baseline, progression is defined as a PSA increase ≥25% and ≥2 ng/mL above baseline after 12 weeks. ^†^tALP/bALP progression for patients with an initial decline in tALP/bALP from baseline was defined as a tALP/bALP increase ≥25% above the nadir, confirmed ≥3 weeks later; for patients with no tALP/bALP decline from baseline, progression was defined as a tALP/bALP increase ≥25% above the baseline after 12 weeks. ^¥^Time to radiographic or clinical progression is a composite end-point encompassing time to first radiographic or clinical progression or death. bALP, bone alkaline phosphatase; CI, confidence interval; PSA, prostate-specific antigen; tALP, total alkaline phosphatase.](nihms-1621413-f0002){#F2}

###### 

Baseline characteristics (phase 2a cohort).

  Characteristic                                         Radium-223 + docetaxel *N* = 33           Docetaxel *N* = 13
  ------------------------------------------------------ ----------------------------------------- ----------------------------------------
  Age, median (range), years                             68 (49--82)                               67 (55--82)
  Weight, median (range), kg                             87 (61--120)                              78 (69--132)
  Karnofsky Performance Status, median %, (range)        90 (70--100)                              90 (70--100)
  Albumin, median, g/L                                   43.0                                      43.0
  Haemoglobin, median, g/L                               122.0                                     121.0
  PSA                                                                                              
   \>ULN, *N* (%)                                        32 (97)                                   13 (100)
   Median (range), \|μg/L                                99 (3--1000)                              43 (4--1042)
  Total ALP                                                                                        
   \>ULN, *N* (%)                                        20 (61)                                   10 (77)
   Median (range), U/L                                   167 (62--1016)                            186 (74--472)
  Bone ALP                                                                                         
   \>ULN, *N* (%)                                        23 (70)                                   11 (85)
   Median (range), μg/L                                  36 (10--331)                              47 (16--164)
  LDH                                                                                              
   \>ULN, *N* (%)                                        6 (18)                                    2 (15)
   Median (range), U/L                                   191 (123--418)                            190 (124--328)
  Patients with visceral metastatic lesions, *N* (%)                                               
   Any                                                   5 (15)                                    2 (15)
    Lung                                                 1 (3)                                     1 (8)
    Liver                                                0                                         0
    Other                                                4^[a](#TFN2){ref-type="table-fn"}^ (12)   l^[b](#TFN3){ref-type="table-fn"}^ (8)
  Extent of disease (number of bone lesions), *N* (%)                                              
   2--4                                                  4 (12)                                    0
   5--9                                                  7 (21)                                    3 (23)
   10--20                                                9 (27)                                    4 (31)
   \>20                                                  13 (39)                                   6 (46)
  Time since initial diagnosis, median (range), months   73 (7--292)                               45 (12--274)
  Time since bone metastases, median (range), months     23 (1--58)                                10 (0--92)
  Prior anticancer therapies, *N* (%)                                                              
   Hormonal therapies                                                                              
    Abiraterone + prednisone                             25 (76)                                   8 (62)
    Enzalutamide                                         3 (9)                                     5 (38)
   Chemotherapy                                                                                    
    Docetaxel                                            2 (6)                                     0
   Immunostimulants                                                                                
    Sipuleucel-T                                         6 (18)                                    4 (31)
   Bone-modifying agents, *N* (%)                                                                  
    Bisphospnonates                                      13 (39)                                   5 (38)
    Denosumab                                            12 (36)                                   3 (23)
   Other, *N* (%)                                                                                  
    Radiation                                            24 (73)                                   9 (69)

ALP, alkaline phosphatase; LDH, lactate dehydrogenase; PSA, prostate-specific antigen; ULN, upper limit of normal.

Adrenal (2 patients), pleura, pancreas.

Adrenal.

###### 

TEAEs in the phase 2a treatment period (any grade and grade 3 or 4): safety population.

  TEAE                                                   Any grade              Grade 3 or 4   
  ------------------------------------------------------ ----------- ---------- -------------- --------
  Any                                                    33 (100)    13 (100)   16 (48)        8 (62)
   Haematological^[a](#TFN6){ref-type="table-fn"}^                                             
    Neutropenia                                          10 (30)     5 (38)     10 (30)        5 (38)
    Anaemia                                              3 (9)       1 (8)      1 (3)          0
    Leucopenia                                           2 (6)       2 (15)     2 (6)          2 (15)
    Lymphopenia                                          1 (3)       0          1 (3)          0
    Febrile neutropenia                                  0           2 (15)     0              2 (15)
   Non-haematological^[b](#TFN7){ref-type="table-fn"}^                                         
    Fatigue                                              17 (52)     9 (69)     0              0
    Nausea                                               16 (48)     8 (62)     0              0
    Diarrhoea                                            15 (45)     5 (38)     1 (3)          0
    Back pain                                            13 (39)     4 (31)     2 (6)          0
    Alopecia                                             12 (36)     7 (54)     0              0
    Peripheral oedema                                    12 (36)     5 (38)     0              1 (8)
    Constipation                                         11 (33)     5 (38)     0              0
    Decreased appetite                                   11 (33)     4 (31)     0              0
    Peripheral neuropathy                                10 (30)     4 (31)     0              0
    Dysgeusia                                            7 (21)      8 (62)     0              0
    Arthralgia                                           7 (21)      6 (46)     0              0
    Dyspnoea                                             2 (6)       5 (38)     0              0
    Gastrointestinal reflux disease                      1 (3)       4 (31)     0              0

TEAEs, treatment-emergent adverse events.

Data are number of patients (%).

Selected because of their relevance to radium-223 and chemotherapy.

Any grade occurring in ≥25% of patients in either treatment group.

[^1]: Current address: Division of Hematology, Oncology and Transplantation, University of Minnesota, Minneapolis, MN, USA.

[^2]: Current address: Department of Medical Sciences, University of Turin Division of Nuclear Medicine, Turin, Italy.
